Traditional and newer therapeutic options for psoriatic arthritis: An evidence-based review

Drugs

Volumn 65, Issue 9, 2005, Pages 1223-1238

  Gladman, Dafna D ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Centre for Prognosis Studies in the Rheumatic Diseases   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIMALARIAL AGENT; AZATHIOPRINE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; ETRETINATE; IBUPROFEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; ONERCEPT; PLACEBO; PREDNISONE; PSORALEN; RETINOIC ACID DERIVATIVE; SALAZOSULFAPYRIDINE;

ARTHRITIS; CLINICAL TRIAL; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE FUNCTION; PATHOGENESIS; PSORIASIS; PSORIATIC ARTHRITIS; QUESTIONNAIRE; REVIEW; T LYMPHOCYTE ACTIVATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 22744457967     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565090-00004     Document Type: Review

References (104)

1. Gladman DD, Rahman P. Psoriatic arthritis. In: Ruddy S, Harris ED, Sledge CB, et al., editors. Kelly's textbook of rheumatolo gy. 6th ed. Philadelphia (PA): WB Saunders, 2001: 1071-9
2. Bruce IN. Psoriatic arthritis clinical features. In: Hochberg M, Silman A, Smolen J, et al., editors. Rheumatology. Edinburgh: Mosby, 2003: 1241-53
3. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4: 441-7
4. Brockbank J, Stein M, Schentag CT, et al. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005 Feb; 64 (2): 188-90. Epub 2004 Jul 22
5. Gladman DD, Brubacher B, Buskila D, et al. Differences in the expression of spondyloarthropathy: a comparison between an kylosing spondylitis and psoriatic arthritis: genetic and gender effects. Clin Invest Med 1993; 16: 1-7
6. Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809-12
7. Torre-Alonso JC, Rodrigues-Perez A, Arribas-Castrillom JM, et al. Psoriatic arthritis (PA): a clinical immunologic and radiological study. Br J Rheumatol 1991; 30: 245-50
8. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003; 42: 778-83
9. Gladman DD, Farewell VT. Progression in psoriatic arthritis: role of time varying clinical indicators. J Rheumatol 1999; 26: 2409-13
10. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001; 28: 1842-6
11. Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001; 45: 151-8
12. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single centre. I: risk and causes of death. Arthritis Rheum 1997; 40: 1873-7
13. Gladman DD, Farewell VT, Wong K, et al. Mortality studies in psoriatic arthritis: results from a single centre. II: prognostic indicators for mortality. Arthritis Rheum 1998; 41: 1103-10
14. Moll JM, Wright V. Familial occurrence of PsA. Ann Rheum Dis 1973; 32: 181-201
15. Eastmond CJ. Genetics and HLA antigens. In: Wright V, Helliwell P, editors. Baillière's clinical rheumatology. Psoriatic arthritis. London: Baillière's Tindall, 1994: 263-76
16. Gladman DD, Farewell VT, Pellett F, et al. HLA is a candidate region for psoriatic arthritis: evidence for excessive HLA sharing in sibling pairs. Hum Immunol 2003; 64: 887-9
17. Elder JT, Nair RP, Henseler T, et al. The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol 2001; 137: 1447-54
18. Karason A, Gudjonsson JE, Upmanyu R, et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 2003; 72: 125-31
19. Gladman DD, Farewell VT, Kopciuk K, et al. HLA antigens and progression in psoriatic arthritis. J Rheumatol 1998; 25: 730-3
20. Gladman DD. Toward unraveling the mystery of psoriatic arthritis. Arthritis Rheum 1993; 36: 881-4
21. Veale D, Yanni G, Rogers S, et al. Reduced synovial membrane macrophage numbers, ELAM1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993; 36: 893-900
22. Ritchlin C, Haas-Smith SA, Hicks D. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25 (8): 1544-52
23. Espinoza LR, Aguilar JL, Espinoza CG, et al. Fibroblast function in psoriatic arthritis: I. Alteration of cell kinetics and growth factor responses. J Rheumatol 1994; 21: 1502-6
24. Espinoza LR, Aguilar JL, Espinoza CG, et al. Fibroblast function in psoriatic arthritis: II. Increased expression of PDGF receptors and increased production of GF and cytokines. J Rheumatol 1994; 21: 1507-11
25. Panayi G. Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol 1994; 8: 419-27
26. Veale DJ, Barnes L, Rogers S, et al. Immunohistochemical markers for arthritis in psoriasis. Ann Rheum Dis 1994; 53: 450-4
27. Costello P, Bresnihan B, O'Farrell C, et al. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999; 26: 1117-24
28. Nakashima T, Wada T, Penninger JM. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003; 15: 280-7
29. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76
30. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-57
31. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821-31
32. Neumüller J, Dunky A, Burtscher H, et al. Interaction of monocytes from patients with psoriatic arthritis with cultured microvascular endothelial cells. Clin Immunol 2001; 98: 143-52
33. Dayer JM, Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw 1994; 5: 563-71
34. Fraser A, Fearon U, Reece R, et al. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001; 44: 2024-8
35. Hitchon CA, Danning CL, Illei GG, et al. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. J Rheumatol 2002; 29: 107-17
36. Ribbens C, Porras M, Franchimont N, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002; 61: 161-6
37. Myers A, Lakey R, Cawston TE, et al. Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings. Rheumatology (Oxford) 2004 Mar; 43 (3): 272-6
38. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. J Rheumatol 1999; 26: 1752-6
39. Gladman DD, Helliwell P, Mease PJ, et al. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004; 50: 24-35
40. Gladman DD, Farewell V, Buskila D, et al. Reliability of measurements of active and damaged joints in psoriatic arthritis. J Rheumatol 1990; 17: 62-4
41. Gladman DD, Cook RJ, Schentag C, et al. The clinical assessment of patients with psoriatic arthritis: results of a validation study of the SpondyloArthritis Research Consortium of Canada (SPARCC). J Rheumatol 2004 Jun; 31 (6): 1126-31
42. Gladman DD, Strand V, Mease PJ, et al. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis 2005 Mar; 64 Suppl. 2: ii115-6
43. Griffith CEM. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheumatol 1997; 36: 409-12
44. Black RL, O'Brien WM, Van Scott EJ, et al. Methotrexate therapy in psoriatic arthritis: double blind study on 21 patients. JAMA 1964; 189: 743-7
45. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27: 376-81
46. Kragballe K, Zachariae E, Zachariae H. Methotrexate in psoriatic arthritis: a retrospective study. Acta Derm Venereol 1983; 63: 165-7
47. Espinoza LR, Zakraoui L, Espinoza CG, et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992; 19: 872-7
48. Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiologic outcome. J Rheumatol 1995; 22: 241-5
49. Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28: 2274-82
50. Spadaro A, Riccieri V, Sili-Scavalli A, et al. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995; 13: 589-93
51. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporin for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277-84
52. Hopkins R, Bird HA, Jones H, et al. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis 1985; 44: 189-93
53. Ciompi ML, Bazzichi L, Marotta G, et al. Tigason (etretinate) treatment in psoriatic arthritis. Int J Tissue React 1988; 10: 25-7
54. Klinkhoff AV, Gertner E, Chalmers A, et al. Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989; 16: 789-91
55. Perlman SG, Gerber LH, Roberts RM, et al. Photochemotherapy and psoriatic arthritis: a prospective study. Ann Intern Med 1979; 91: 717-22
56. de Misa RF, Azana JM, Harto A, et al. Psoriatic arthritis: one year of treatment with extracorporeal photochemotherapy. J Am Acad Dermatol 1994; 30: 1037-8
57. Farr M, Kitas GD, Waterhouse L, et al. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990; 29: 46-9
58. Fraser SM, Hopkins R, Hunter JA, et al. Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 1993; 32: 923-5
59. Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995; 22: 894-8
60. Combe B, Goupille P, Kuntz JL, et al. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996; 35: 664-8
61. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-20
62. Rahman P, Gladman DD, Zhou Y, et al. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998; 25: 1957-61
63. Levy JJ, Paulus HE, Barnett EV, et al. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972; 15: 116-7
64. Lee JCT, Gladman DD, Schentag CT, et al. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol 2001; 7: 160-5
65. Gladman DD, Blake R, Brubacher B, et al. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992; 19: 1724-6
66. Carrette S, Calin A. Evaluation of auranofin in psoriatic arthritis: a double blind placebo controlled trial. Arthritis Rheum 1989; 32: 158-65
67. Palit J, Hill J, Capell HA, et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990; 29: 280-3
68. Mader R, Gladman DD, Long J, et al. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis. Clin Invest Med 1995; 18: 139-43
69. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review). In: The Cochrane Library. Issue 3. Oxford: Update Software, 2001: 1-18
70. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004; 50: 1939-50
71. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90
72. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum 2004; 50: 2264-72
73. Antoni C, Kavanaugh A, Kirkham B, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [abstract]. Arthritis Rheum 2002; 46: S381
74. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005; 52: 1227-36
75. Kavanaugh A, Krueger GG, De Vlam K, et al. Infliximab improves arthritis and psoriasis in patients with active polyar-ticular psoriatic arthritis: results of the IMPACT 2 trial [abstract]. Ann Rheum Dis 2004; 63 Suppl. 1: 402
76. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase II study [abstract]. Arthritis Rheum 2004; 50: 4097
77. Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000; 43: 495-505
78. Breedveld FC, Dayer J-M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841-9
79. Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol 2001; 7: 366-70
80. Reich K, Hummel KM, Beckmann I, et al. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol 2002; 146: 335-6
81. Cuchacovich M, Soto L. Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis. Ann Rheum Dis 2002; 61: 942-3
82. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44
83. Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 151-8
84. Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6
85. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17: 681-4
86. Schrader P, Mooser G, Peter RU, et al. Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil [in German]. Z Rheumatol 2002; 61: 545-50
87. Grundmann-Kollmann M, Mooser G, Schraeder P, et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000; 42: 835-7
88. Specner-Green G. Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 2000; 59 Suppl. 1: i46-9
89. Mease P. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S116-21
90. Remicade® [manufacturer's prescribing information]. Malvern (PA): Centocor Inc., 2002
91. Feletar M, Brockbank JB, Schentag C, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004; 63: 156-61
92. Serono web page: media [online]. Available from URL: http://www.serono. com/media/stories2003/20030622 [Accessed 2004 Sep 01]
93. Serono announces discontinuation of onercept in moderate-to-severe psoriasis and Canvaxin™ in stage IV melanoma. Press release; 2005 Apr 6 [online]. Available from URL: http://www.serono.com/media/stories2005/ archive2005.jsp?major=4=1 [Accessed 2005 Apr 14]
94. Keystone ED, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004; 50: 1400-11
95. Ritchlin C, Anandarajaha A, Totterman S, et al. Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis [abstract]. Ann Rheum Dis 2004; 63 Suppl. 1: 403
96. Langley R, Leonardi C, Toth D, et al. Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis [abstract]. J Am Acad Dermatol 2005; 52 (3 Suppl.): 2
97. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285: 221-7
98. Leonardi CL. Treatment of psoriasis using efalizumab. In: Weinstein G, Gottlieb A, editors. Therapy of moderate-to-severe psoriasis. New York: Marcel Dekker, 2003: 333-50
99. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349 (21): 2004-13
100. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290 (23): 3073-80
101. Genentech and Xoma announce results of phase II study of Raptiva™ in psoriatic arthritis patients [news release; online]. Available from URL: http://www.xoma.com/pdf/nr_04.03.21.pdf [Accessed 2004 Sep 01]
102. Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002; 46: 2776-84
103. Krueger G, Callis K. Alefacept to treat psoriasis. In: Weinstein G, Gottlieb A, editors. Therapy of moderate-to-severe psoriasis. New York: Marcel Dekker, 2003: 287-306
104. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-55